{"id":"sanorg34006","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Headache"},{"rate":"5-10%","effect":"Dizziness"}]},"_chembl":{"chemblId":"CHEMBL5314374","moleculeType":"Oligosaccharide","molecularWeight":"1727.19"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting Nav1.5, SanOrg34006 is expected to reduce the frequency of atrial fibrillation episodes. This is achieved by stabilizing the cardiac action potential and reducing the excitability of atrial myocytes.","oneSentence":"SanOrg34006 is a small molecule that acts as a selective inhibitor of the sodium-activated potassium channel, Nav1.5.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:33:29.369Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Atrial fibrillation for stroke prevention"}]},"trialDetails":[{"nctId":"NCT00311090","phase":"PHASE3","title":"Bioequipotency Study of Idrabiotaparinux and Idraparinux in Patients With Deep Venous Thrombosis of the Lower Limbs","status":"COMPLETED","sponsor":"Sanofi","startDate":"2006-04","conditions":"Deep Venous Thrombosis","enrollment":757},{"nctId":"NCT00345618","phase":"PHASE3","title":"Clinical Study Assessing Idrabiotaparinux Sodium Injections Once-weekly in Pulmonary Embolism Therapeutic Approach","status":"COMPLETED","sponsor":"Sanofi","startDate":"2006-06","conditions":"Embolism, Thrombosis","enrollment":3202},{"nctId":"NCT00580216","phase":"PHASE3","title":"Evaluation of Weekly Idrabiotaparinux Sodium Versus Oral Adjusted-dose Warfarin to Prevent Stroke and Systemic Thromboembolic Events in Patients With Atrial Fibrillation","status":"TERMINATED","sponsor":"Sanofi","startDate":"2007-12","conditions":"Atrial Fibrillation","enrollment":3773},{"nctId":"NCT00071279","phase":"PHASE3","title":"SR34006 Compared to Placebo in Patients Who Have Completed 6 Months of Treatment for Symptomatic Pulmonary Embolism or Deep Vein Thrombosis","status":"COMPLETED","sponsor":"Sanofi","startDate":"2003-11","conditions":"Pulmonary Embolism, Deep Vein Thrombosis","enrollment":1215},{"nctId":"NCT00067093","phase":"PHASE3","title":"Safety and Efficacy Trial Evaluating the Use of SR34006 in the Treatment of Deep Vein Thrombosis (DVT)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2003-05","conditions":"Deep Vein Thrombosis","enrollment":1452},{"nctId":"NCT00070655","phase":"PHASE3","title":"Evaluating the Use of SR34006 Compared to Warfarin or Acenocoumarol in Patients With Atrial Fibrillation (AMADEUS)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2003-09","conditions":"Atrial Fibrillation","enrollment":4673},{"nctId":"NCT00062803","phase":"PHASE3","title":"SR34006 Compared to Vitamin K Antagonist (VKA) in the Treatment of Pulmonary Embolism","status":"COMPLETED","sponsor":"Sanofi","startDate":"2003-06","conditions":"Pulmonary Embolism","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"SanOrg34006","genericName":"SanOrg34006","companyName":"Sanofi","companyId":"sanofi","modality":"Small molecule","firstApprovalDate":"","aiSummary":"SanOrg34006 is a small molecule that acts as a selective inhibitor of the sodium-activated potassium channel, Nav1.5. Used for Atrial fibrillation for stroke prevention.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}